WPD Pharmaceuticals Inc.

WBIO

CA92941F1053

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 07:19:31 28/06/2022 pm IST			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	-.--%

08/05	WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/02	WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Westcot Ventures Corp. has Changed its Name to WPD Pharmaceuticals Inc

January 14, 2020 at 10:30 am IST

On January 14, 2020, Westcot Ventures Corp. changed its name to WPD Pharmaceuticals Inc.

Latest news about WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/05	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/02	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/02	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/01	CI
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding	15/23/15	CI
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	02/23/02	CI
WPD Pharmaceuticals Inc. Announces Directorate Appointments	02/23/02	CI
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding	01/23/01	CI
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	18/23/18	CI
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	19/22/19	CI
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	06/22/06	CI
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022	25/22/25	CI
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding	14/22/14	CI
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16/22/16	CI
WPD Pharmaceuticals Inc. Signs Consortium Agreement on EuroNanoMed Project	07/22/07	CI
WPD Pharmaceuticals Inc. Announces Appointment of Romuald Harwas as a Director	03/22/03	CI
WPD Pharmaceuticals Inc. Secures Berubicin Sub-License Rights in Perpetuity	01/22/01	CI
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3 Million Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML	16/21/16	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	30/21/30	CI
WPD Pharmaceuticals Plans to Go Public in Poland	02/21/02	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	31/21/31	CI
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in Second Half of 2021	28/21/28	CI
WPD Pharmaceuticals Inc. Joins International Research Consortium	10/21/10	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	04/21/04	CI
WPD Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	03/21/03	CI

Chart WPD Pharmaceuticals Inc.

Duration

Period

More charts

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WPD PHARMACEUTICALS INC.	-.--%	3.73M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B